Podcast: Gillian Woollett on the Future of Biologics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Podcast: Gillian Woollett on the Future of Biologics


Gillian R. Woollett on The Future of Biologics

Chief Scientist at Engel & Novitt, a law firm specializing in biologic standards and public policy, Gillian R. Woollett discusses the changing landscape of biologics, biosimilars, related harmonization efforts, and more. Recorded LIVE at the USP 2011 Science and Standards Symposium, October 2011, where Woollette was a keynote speaker.
Interviewed by Angie Drakulich, senior managing editor

Related podcast with USP's Tina Morris

Related podcast with USP's Matthew van Hook

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here